...
首页> 外文期刊>Oncology letters >Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patients
【24h】

Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patients

机译:使用CT图像的肥胖定量测量预测上皮性卵巢癌患者中北伐木基化学疗效的益处

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The present study aims to quantitatively measure adiposity-related image features and to test the feasibility of applying multivariate statistical data analysis-based prediction models to generate a novel clinical marker and predict the benefit of epithelial ovarian cancer (EOC) patients with and without maintenance bevacizumab-based chemotherapy. A dataset involving computed tomography (CT) images acquired from 59 patients diagnosed with advanced EOC was retrospectively collected. Among them, 32 patients received maintenance bevacizumab following primary chemotherapy, while 27 did not. A computer-aided detection scheme was developed to automatically segment visceral and subcutaneous fat areas depicted on CT images of abdominal sections, and 7 adiposity-related image features were computed. Upon combining these features with the measured body mass index, multivariate data analyses were performed using three statistical models (multiple linear, logistic and Cox proportional hazards regressions) to analyze the association between the model-generated prediction results and the treatment outcome, including progression-free survival (PFS) and overall survival (OS) of the patients. The results demonstrated that applying all three prediction models yielded a significant association between the adiposity-related image features and patients' PFS or OS in the group of the patients who received maintenance bevacizumab (P<0.010), while there was no significant difference when these prediction models were applied to predict both PFS and OS in the group of patients that did not receive maintenance bevacizumab. Therefore, the present study demonstrated that the use of a quantitative adiposity-related image feature-based statistical model may generate a novel clinical marker to predict who will benefit among EOC patients receiving maintenance bevacizumab-based chemotherapy.
机译:本研究旨在定量测量肥胖相关的图像特征,并测试应用多元统计数据分析的预测模型的可行性,以产生新的临床标志物,并预测上皮性卵巢癌(EOC)患者的益处,无需维护Bevacizumab基于化疗。回顾性收集了从诊断出患有高级EOC的59名患者获取的计算断层扫描(CT)图像的数据集。其中,32例患者在初级化疗后接受维护贝伐单抗,而27则没有。开发了一种计算机辅助检测方案以自动分割腹部CT图像上描绘的内脏和皮下脂肪区域,并且计算了7个肥胖相关的图像特征。将这些特征与测量的体重指数组合起来时,使用三种统计模型(多线性,逻辑和Cox比例危害回归)进行多变量数据分析,以分析模型产生的预测结果和治疗结果之间的关联,包括进展 - 自由存活(PFS)和患者的总体存活(OS)。结果表明,应用所有三种预测模型在接受维护贝伐单抗的患者组(P <0.010)的患者中肥胖相关的图像特征和患者的PFS或OS之间产生了重大关联(P <0.010),而当这些时没有显着差异应用预测模型以预测未收到维护贝伐单抗的患者组中的PFS和OS。因此,本研究表明,使用定量肥胖相关的图像特征基统计模型可以产生新的临床标记,以预测谁将受益于接受维护贝伐单抗的化疗的EOC患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号